Progress in the Treatment of Hodgkin’s Lymphoma
Mené sur 1 334 patients atteints d'un lymphome classique de Hodgkin de stade III ou IV (durée médiane de suivi : 24,9 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du brentuximab védotin à une chimiothérapie (doxorubicine, vinblastine et dacarbazine, avec ou sans bléomycine)
Although there has been considerable research activity in the treatment of Hodgkin’s lymphoma since advanced stages of the disease became curable with combination chemotherapy in the 1960s, the most significant advances have involved the maintenance of a particular level of antitumor efficacy while acute and late toxic side effects and their attendant mortality are reduced. These advances include the preservation of high response rates at reduced levels of toxicity with the current standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); the demonstration that various forms of radiation therapy were associated with unacceptably high levels of long-term toxicity; the application (...)
New England Journal of Medicine , éditorial, 2017